Business
Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation
VANCOUVER, BC / ACCESS Newswire / May 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Inka Health Corp. ("Inka Health"), the Company's wholly owned subsidiary, ...
About this update from Onco-innovations Ltd.
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / May 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Inka Health Corp. ("Inka Health"), the Company's wholly owned subsidiary, has started a collaborative research agreement (the "Agreement" or "Project" or "Work") with GlaxoSmithKline LLC ("GSK"). Under the Agreement, Inka Health and GSK intend to collaborate to develop real-world data-driven methodologies aimed at improving the transportability of oncology clinical trial results across broader patient populations, geographies, and healthcare settings, with a view to helping to make clinical evidence more relevant to real-world decision-making.","length":805,"tagName":"p"},{"type":"text","content":"As part of the Project, Onco's wholly-owned subsidiary, Inka Health, will contribute its expertise in advanced analytics, including machine learning and causal inference methods, and work with GSK Epidemiology and RWE experts with the aim of helping to develop a conceptual and methodological framework for the use of real-world data to support the transportability of clinical trials. Work is expected to include a comprehensive literature review on transportability methodologies as well as the design of a structured evaluation framework and retrospective testing and validation using publicly available oncology datasets and use cases. The Project is also expected to contribute to jointly authored scientific manuscripts with contributors from both Inka Health and GSK.","length":778,"tagName":"p"},{"type":"text","content":""We are pleased to work with Inka Health on this important area of evidence generation. As the use of real-world data continues to evolve, there is growing interest in methodologies that can help evaluate how clinical trial findings may translate across broader patient populations and care settings. We believe this work can contribute to the ongoing scientific dialogue in oncology and support more rigorous approaches to understanding the applicability of clinical evidence in real-world contexts," said Rodrigo Refoios Camejo, Executive Director of RWE Science & Innovation at GSK.","length":599,"tagName":"p"},{"type":"text","content":"The initiative is fo...